Totally Robotic Versus Surgeon-Assisted Robotic Lung Resection For Early-Stage NSCLC - Trial NCT06348030
Access comprehensive clinical trial information for NCT06348030 through Pure Global AI's free database. This phase not specified trial is sponsored by St. Joseph's Healthcare Hamilton and is currently Not yet recruiting. The study focuses on Lung Cancer. Target enrollment is 120 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
St. Joseph's Healthcare Hamilton
Timeline & Enrollment
N/A
Apr 01, 2024
Mar 01, 2026
Primary Outcome
Costs of Totally Robotic versus Surgeon-Assisted Robotic Lung Resection
Summary
Robotic-assisted thoracoscopic surgery (RTS) is safe and effective for patients with
 early-stage non-small cell lung cancer (NSCLC). During RTS, division, dissection, and sealing
 of lung tissue, bronchi, and blood vessels can be performed using handheld staplers with
 assistance from a bedside surgeon (Surgeon-Assisted), or totally robotically with robotic
 staplers and energy devices by the console surgeon (Totally Robotic). Totally Robotic lung
 resection enables the operating surgeon to perform the case independently, but its
 implication on costs and patient outcomes remains unknown. There also is, however, a lack of
 prospective research evaluating the costs of the two methods for dissection and vessel
 sealing in RTS. This RCT aims to evaluate the costs and perioperative patient outcomes of
 Totally Robotic lung resection using the Vessel Sealer Extend energy device (for vessels
 7mm) and the SureForm robotic stapler (Intervention) versus Surgeon-Assisted robotic lung
 resection using the Signia stapler (Control) during RTS for NSCLC using the da Vinci system.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06348030
Device Trial